X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoies
about
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosisMyeloid malignancies: mutations, models and managementA germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasmsHow ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes.Thrombopoietin and hematopoietic stem cells.Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.A mathematical framework to determine the temporal sequence of somatic genetic events in cancerDistinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signalingProteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera.X-linked clonality testing: interpretation and limitationsThe Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues.MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemiaCD133 marks a stem cell population that drives human primary myelofibrosis.Mechanisms of thrombogenesis in polycythemia veraMolecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expressionTelomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms.TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosisThe role of Janus kinases in haemopoiesis and haematological malignancy.JAK2 V617F, MPL W515L and JAK2 Exon 12 Mutations in Chinese Patients with Primary MyelofibrosisHigh-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.Stat5 as a diagnostic marker for leukemia.Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.Genetic complexity of myeloproliferative neoplasms.A progenitor cell origin of myeloid malignanciesKinase drug discovery approaches in chronic myeloproliferative disorders.Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues.Recent developments on JAK2 inhibitors: a patent review.Potential of human induced pluripotent stem cells derived from blood and other postnatal cell types.Myeloproliferative neoplasm animal modelsAdvances in molecular diagnostics of myeloproliferative disorders.Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).JAK2V617F mediates resistance to DNA damage-induced apoptosis by modulating FOXO3A localization and Bcl-xL deamidation.Prognosis of Primary Myelofibrosis in the Genomic EraValidation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples.X-chromosome inactivation pattern analysis for the assessment of cell clonality in cats.
P2860
Q24609999-A300402B-B7E9-41DF-813A-3E7F955B2333Q27000577-75DD1221-A871-471D-84AC-9C18FD13DA60Q27851467-2A739872-C456-4AF9-B54E-B8930C2F9439Q30240043-076A4128-1090-4546-B9F9-4134C4D8C377Q33394846-32ACD784-1AA3-43A1-B403-2CF5DB5A0E98Q33586552-D3A94D88-80BF-4085-8D44-C82C4A364380Q33697252-5C52D7CD-EEDA-4358-8081-20B1ADD2860AQ34162729-97115E90-D210-4BA5-B91D-E9D3504816AAQ34200279-B7AAD261-F04D-47E0-BB97-E3A9D7B4DA27Q34378552-F4ED4113-E599-4170-A916-D2E7028AF5ADQ34477649-2172AAEA-78FD-40AE-8390-6487CFE12B58Q34619256-79FE2B23-F93F-4265-8D15-C780AF5F346FQ34750582-C52F1BC2-FA2D-46E0-ABE8-A5C820C6ECB0Q34770384-328AB09E-F142-49C9-B68C-1AABE359907AQ35217865-C9229EE4-F57E-4222-B87D-1B890CD8D063Q35669866-E5B9C064-2336-43EB-B484-947EF6D62912Q35738656-5DF3EDDC-F4F2-46D7-99A7-480F4E94B741Q35848857-71AF8DF7-3CFD-4A20-B19C-157F9933C092Q36267858-6E4EB126-C203-4A0B-8347-35BBB47594B3Q36303447-45ABCD1F-1B40-4BA6-B841-B3866330E4CEQ36527760-AC44017C-D727-4980-99AD-F331C2D9C235Q36563107-B4F8D199-AE41-4E1E-9701-D3B240B153B9Q36591388-196FC149-7658-49E7-A8A1-47B27CC1FEA4Q36612537-E0137F20-1A6A-4591-AD00-C65D5A2A8907Q37035281-CE1D04ED-F615-4E4D-8298-246B18AC6FDBQ37250169-90EAC368-526B-47C6-9FF3-70E80F4D58F8Q37255016-D841A2BE-A688-4558-AD6E-8B66F914A279Q37255024-3804551F-FABB-4A83-A3C9-6C2173FDE234Q37377284-5AD576E2-CB3B-4E15-BAD8-36A57DB28B14Q37472874-7C914F14-5121-4A49-9B61-E89BD1C9A1BBQ37566249-CC482BF1-DE91-498C-ACD7-809433FADABDQ37703253-64F28CD8-9FA7-4FC1-9FC8-1A68718BAB03Q37772900-9DAD7974-B6FA-4826-94C8-8CAFE782B8C5Q38046320-F77713E1-F864-4F8F-9C96-DEA423E3E1D3Q38089228-FC595527-E447-4ECB-BB22-6E7FB13E3952Q38699339-40A2EEE2-4373-429F-AB7D-63F3905B4A95Q38847266-6D18EC2D-7DD2-4979-A5DF-11458E2CB42DQ38926804-1F405CB8-4A1A-4F1E-8A40-2E129304B1B6Q39174283-0BFFE568-C734-4534-AC58-6948002852F4Q39374441-46C71726-9BA7-4C0E-8B5A-8E30DB8B82E3
P2860
X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoies
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
X-inactivation-based clonality ...... tients with clonal hematopoies
@ast
X-inactivation-based clonality ...... tients with clonal hematopoies
@en
type
label
X-inactivation-based clonality ...... tients with clonal hematopoies
@ast
X-inactivation-based clonality ...... tients with clonal hematopoies
@en
prefLabel
X-inactivation-based clonality ...... tients with clonal hematopoies
@ast
X-inactivation-based clonality ...... tients with clonal hematopoies
@en
P2093
P2860
P1433
P1476
X-inactivation-based clonality ...... tients with clonal hematopoies
@en
P2093
Claude Belisle
D Gary Gilliland
David Zahrieh
Lambert Busque
Pierre Chagnon
Ross L Levine
Stephanie Lee
P2860
P304
P356
10.1182/BLOOD-2005-09-3900
P407
P577
2006-01-24T00:00:00Z